US 1995 Drug Price Rises Were 4.6%, Says NACDS

26 February 1996

For 1995 as a whole, pharmaceutical manufacturer price rises in the USA exceeded those of the Consumer Price Index. According to a statement from the National Association of Chain Drug Stores, the manufacturer price of the top 500 drugs dispensed in community pharmacies continued their upward spiral, rising 4.6%.

In contrast, the overall general inflation rate in 1995, as measured by the CPI, was 2.4%. However, the CPI index for prescription medicines specifically, the CPI-Rx, was 2% for 1995.

The rise of 4.6%, as measured by the NACDS Prime Index, is said to be consistent with the trend of rising drug prices as reflected in recent findings of the US Department of Labor's Bureau of Labor Statistics, which reported a 4.2% increase in 1995 prices for pharmaceuticals measured by the Producer Price Index (PPI-Rx). This 4.2% level is the highest increase in three years, according to the BLS, as was the NACDS' reported 4.6%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight